MARX Biotech Co (ROCO:7731) EBIT: NT$71.5 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7731 MARX Biotech Co Ltd ROCO:7731
10 GF Score
Price NT$4.87
! 4 Warning Signs
View Full Analysis

What is MARX Biotech Co EBIT?

MARX Biotech Co ROCO:7731 -3.18% 10 EBIT is NT$71.5 Mil as of Dec. 2025. GuruFocus rates ROCO:7731 with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

MARX Biotech Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was NT$104.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$71.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. MARX Biotech Co's annualized ROC % for the quarter that ended in Dec. 2025 was -25.60%. MARX Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 60.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. MARX Biotech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 2.54%.

MARX Biotech Co  (ROCO:7731) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

MARX Biotech Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-198.49 * ( 1 - 17.67% )/( (602.547 + 673.964)/ 2 )
=-163.416817/638.2555
=-25.60 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=733.009 - 102.507 - ( 27.955 - max(0, 342.364 - 396.345+27.955))
=602.547

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=832.716 - 123.984 - ( 34.768 - max(0, 307.88 - 548.271+34.768))
=673.964

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

MARX Biotech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=209.272/( ( (221.99 + max(219.96, 0)) + (209.158 + max(41.468, 0)) )/ 2 )
=209.272/( ( 441.95 + 250.626 )/ 2 )
=209.272/346.288
=60.43 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(85.926 + 243.589 + 34.948) - (102.507 + 0 + 41.996)
=219.96

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(66.649 + 110.456 + 28.654) - (123.984 + 0 + 40.307)
=41.468

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

MARX Biotech Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=71.47/2815.033
=2.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MARX Biotech Co EBIT Related Terms

MARX Biotech Co EBIT Historical Data

* Premium members only.

The historical data trend for MARX Biotech Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MARX Biotech Co EBIT Chart

MARX Biotech Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 17.69 5.02 -15.12 -95.22 71.47

MARX Biotech Co Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.68 -50.89 -44.33 -33.17 104.64

MARX Biotech Co EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, MARX Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MARX Biotech Co EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MARX Biotech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MARX Biotech Co's EV-to-EBIT falls into.


ROCO:7731
10GF Score
MARX Biotech Co Ltd ROCO:7731
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MARX Biotech Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$71.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$71.5 Mil mean?
MARX Biotech Co (ROCO:7731) has a EBIT of NT$71.5 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MARX Biotech Co.
Is MARX Biotech Co's EBIT too high?
MARX Biotech Co's current EBIT is NT$71.5 Mil. Overall, MARX Biotech Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does MARX Biotech Co's EBIT compare to competitors?
MARX Biotech Co's EBIT of NT$71.5 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on MARX Biotech Co. MARX Biotech Co's current EBIT is NT$71.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MARX Biotech Co stock overvalued right now?
MARX Biotech Co (ROCO:7731) has a current EBIT of NT$71.5 Mil. The current EBIT is NT$71.5 Mil. MARX Biotech Co's overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For MARX Biotech Co (ROCO:7731), the current EBIT is NT$71.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MARX Biotech Co Business Description

Address 5th Floor, No. 655, Bannan Road, Zhonghe district, New Taipei, TWN
MARX Biotech Co Ltd is a retail company which has developed an O2O and OMO full-channel layout in the online Internet platform and cosmeceutical retail market, and has successfully established itself in the market and Build trust and operational growth on the channel side. It has has established more than three thousand large and small cosmeceutical pharmacies in Taiwan, including: Dashu Pharmacy, Dingding Pharmacy, Cosmed, Watsons, Spring Pharmacy, New Gaoqiao Pharmacy, Anlier Pharmacies, etc.
10GF Score

Get the complete analysis for ROCO:7731

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$4.87
Price